한글목차

본 보고서는 리지니라졸(Ridinilazole) 신약 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)을 조사 분석하여 작용기전, 용법 및 용량, 연구개발 활동에 대한 고찰과 시장 전망 등을 제공합니다.

목차

제1장 보고서 서론

제2장 크로스트리듐디피실 감염증용 리지니라졸 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 새로운 치료법)

제5장 리지니라졸 시장 평가

• 크로스트리듐디피실 감염증용 리지니라졸 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 크로스트리듐디피실 감염증용 리지니라졸 시장 규모
• 시장 분석 : 국가별
  • 미국의 크로스트리듐디피실 감염증용 리지니라졸 시장 규모
  • 독일의 크로스트리듐디피실 감염증용 리지니라졸 시장 규모
  • 영국의 크로스트리듐디피실 감염증용 리지니라졸 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

“"Ridinilazole Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ridinilazole for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the ridinilazole for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ridinilazole for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ridinilazole market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

Ridinilazole (previously known as SMT19969), being developed by Summit Therapeutics, is an investigational bisbenzimidazole oral antimicrobial that targets C. difficile whilst sparing the gut microbiome and producing protective secondary bile acids; it is highly specific and bactericidal against C. difficile.

In the clinical trials, ridinilazole achieved a numerically higher sustained clinical response rate than vancomycin but did not achieve the pre-specified superiority endpoint. Summit Therapeutics has discontinued its only active study for ridinilazole, a pediatric clinical trial evaluating the drug for treating adolescent patients with CDI. It is looking for partners or divestiture of ridinilazole as the path forward for the clinical development of the asset.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ridinilazole description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on ridinilazole regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ridinilazole research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ridinilazole.
• The report contains forecasted sales of ridinilazole for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for ridinilazole in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ridinilazole Analytical Perspective by DelveInsight

In-depth Ridinilazole Market Assessment

This report provides a detailed market assessment of ridinilazole for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Ridinilazole Clinical Assessment

The report provides the clinical trials information of ridinilazole for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ridinilazole dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to ridinilazole and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ridinilazole in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of ridinilazole from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ridinilazole in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of ridinilazole?
• What is the clinical trial status of the study related to ridinilazole in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ridinilazole development?
• What are the key designations that have been granted to ridinilazole for clostridium difficile infection?
• What is the forecasted market scenario of ridinilazole for clostridium difficile infection?
• What are the forecasted sales of ridinilazole in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ridinilazole for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. Ridinilazole Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Ridinilazole Market Assessment

• 5.1. Market Outlook of Ridinilazole in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Ridinilazole in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Ridinilazole in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of Ridinilazole in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of Ridinilazole in France for Clostridium difficile infection
  • 5.3.4. Market Size of Ridinilazole in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of Ridinilazole in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of Ridinilazole in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of Ridinilazole in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options